CD4 and neoplasm: When tested on BALB/c mice, the in vivo findings complemented in vitro studies in that LPPR could aid anti-PD-L1 to overcome its resistance by damaging CAFs and improving anti-tumor immunity, as indicated by increased cytotoxic T cell (i.e., CD3+, CD8+ and CD4+) infiltration to the tumor.